Abstract
In breast cancer, overexpression of HER2 is associated with an aggressive tumor phenotype and poor prognosis. Lapatinib has demonstrated benefit in combination with capecitabine in patients with HER2-positive locally advanced and metastatic breast cancer that has progressed after prior treatment with an anthracycline, a taxane, and trastuzumab. It has also demonstrated benefit with paclitaxel in patients with metastatic disease not previously treated with chemotherapy. This review discusses results from clinical trials suggesting an advantage with the use of lapatinib with other treatment modalities in the setting of metastatic and locally advanced disease.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 10-17 |
| Number of pages | 8 |
| Journal | Current oncology reports |
| Volume | 10 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2008 |
ASJC Scopus subject areas
- Oncology